# The Mediating Factor of Immune Cell in the Causal Relationship Between Cardiovascular Disease‐Related Plasma Proteins and Parkinson’s Disease: A Network Mendelian Randomization Analysis

**Authors:** Ruotong Yao, Siyao Chen, Yangguang Lu, Yiquan Li, Bohuai Yu, Yingying Liu, Tingxuan Zhang, Yusheng Zhu, Feng Chen, Yuhan Lin, Yukai Wang, Cai Li

PMC · DOI: 10.1155/mi/7919308 · 2026-03-04

## TL;DR

This study explores how immune cells might link cardiovascular disease proteins to Parkinson's disease using genetic data and causal analysis.

## Contribution

The study identifies specific immune cell phenotypes that mediate the causal relationship between cardiovascular disease-related proteins and Parkinson’s disease.

## Key findings

- Elevated Fas cell surface death receptors and nerve growth factor are associated with reduced Parkinson’s disease risk.
- Thrombomodulin levels are a risk factor for Parkinson’s disease.
- Four immune phenotypes mediate the association between cardiovascular disease-related proteins and Parkinson’s disease.

## Abstract

Cardiovascular diseases (CVDs) and their associated plasma proteins exhibit significant correlations with immunity and Parkinson’s disease (PD). However, the specific contributions to the risk of developing PD remain unclear. This study aims to investigate the potential causal relationship between CVD‐related plasma proteins and the risk of PD and explore the significant mediating role of immune cell phenotypes.

Using publicly available genetic data, we conducted Mendelian randomization (MR) analysis using the inverse variance weighting method to explore the causal relationship between 83 CVD‐related plasma proteins and PD. Various MR analysis models were employed for sensitivity analysis. Concurrently, we utilized bioinformatics methods such as protein–protein interaction networks and pathway enrichment analysis to investigate the potential associations between CVD‐related plasma proteins and PD‐related genes. Finally, we employed a mediator MR design to identify the mediating effects of 731 immune cell phenotypes in the onset of PD.

Elevated levels of Fas cell surface death receptors (p = 0.015) and nerve growth factor (p = 0.026) are associated with a reduced risk of PD, while increased levels of thrombomodulin (p = 0.028) are a risk factor for PD. Four immune phenotypes play a significant mediating role in the association between CVD‐related proteins and the pathogenesis of PD. Sensitivity analysis indicates that the results are robust.

Our study elucidates the close genetic association between CVD‐related plasma proteins and PD and identifies the significant mediating role of immune cells, thereby providing valuable insights for future research and clinical applications.

## Linked entities

- **Diseases:** cardiovascular disease (MONDO:0004995), Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Genes:** TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, CD33 (CD33 molecule) [NCBI Gene 945] {aka CD33rSiglec, SIGLEC-3, SIGLEC3, p67}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, SULT1A3 (sulfotransferase family 1A member 3) [NCBI Gene 6818] {aka HAST, HAST3, M-PST, ST1A3, ST1A3/ST1A4, ST1A4}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, CD27 (CD27 molecule) [NCBI Gene 939] {aka S152, S152. LPFS2, T14, TNFRSF7, Tp55}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD24 (CD24 molecule) [NCBI Gene 100133941] {aka CD24A}, THBD (thrombomodulin) [NCBI Gene 7056] {aka AHUS6, BDCA-3, BDCA3, CD141, THPH12, THRM}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, CD70 (CD70 molecule) [NCBI Gene 970] {aka CD27-L, CD27L, CD27LG, LPFS3, TNFSF7, TNLG8A}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}
- **Diseases:** neurological disorders (MESH:D009461), multiple sclerosis (MESH:D009103), rigidity (MESH:D009127), glaucoma (MESH:D005901), coronary artery disease (MESH:D003324), stroke (MESH:D020521), noncommunicable diseases (MESH:D000073296), neuronal damage (MESH:D009410), depression (MESH:D003866), toxicity (MESH:D064420), Neuroinflammation (MESH:D000090862), AD (MESH:D000544), neuropsychiatric conditions (MESH:D001523), Cardiovascular Disease (MESH:D002318), neuropsychiatric ailments (MESH:C000631768), bradykinesia (MESH:D018476), tremors (MESH:D014202), PD (MESH:D010300), mitochondrial dysfunction (MESH:D028361), neurodegeneration (MESH:D019636), inflammation (MESH:D007249), epilepsy (MESH:D004827), ALS (MESH:D000690)
- **Chemicals:** 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MESH:D015632), retinol (MESH:D014801), TM (MESH:D013932)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960748/full.md

---
Source: https://tomesphere.com/paper/PMC12960748